Asia-Pacific In-Vitro Fertilization (IVF) Services Market by Cycle Type and End Users - Opportunity Analysis and Industry Forecast, 2014-2022

  • ID: 4033362
  • Report
  • Region: Asia Pacific
  • 235 pages
  • Allied Analytics LLP
1 of 6

FEATURED COMPANIES

  • Auxogyn Inc.
  • Cook Medicals
  • Cooper Surgical. Inc.
  • EMD Serono Inc.
  • Genea Biomedx
  • Irvine Scientific Inc.
  • MORE
Asia-Pacific In-Vitro Fertilization (IVF) Services Market by Cycle Type (Fresh Cycle, Thawed IVF Cycle, and Donor Egg IVF Cycles) and End Users (Fertility Clinics, Hospitals, Surgical Centres, and Clinical Research Institutes) - Opportunity Analysis and Industry Forecast, 2014-2022

In-vitro fertilization is a type of assisted reproductive technology that helps women in conceiving. The Asia Pacific IVF services market, valued at $3.0 billion in 2015, is estimated to reach $7.1 billion by 2022. Delayed pregnancy in women is one of the major driving factors of the embryo transfer market, as the chances of conceiving lowers with age. Success rate of getting pregnant with embryo transfer technique reduces with increase in age. Other driving factors of the embryo transfer market are rise in infertility rate due to rise in stress levels, change in life style and fertility related diseases. Globally, around 15% of the couples faces infertility issues in which males contribute to 20-30% of the overall cases.

The major limiting factors of this market are the cost involved and lower success rates in the treatment. Patients may not conceive in the first cycle of embryo transfer procedure. Patients have to undergo many cycles to achieve pregnancy, and this adds to the overall cost. The average cost of this procedure is approximately $3,000- $8,000. This acts as a major limitation, in adoption of the technique, for people with low income. Another challenge is the low level of awareness in the developing economies such as Nigeria, India, Indonesia among others. Awareness can be created through medical tourism and availability of low cost embryo transfer treatments. The companies profiled in this report include Vitrolife AB, Cooper Surgical. Inc., Cook Medicals, Thermo Fisher Scientific, Irvine Scientific Inc., Genea Biomedx, Oxford Gene Technology, Auxogyn Inc., EMD Serono Inc. and Ovascience Inc.

KEY BENEFITS FOR STAKEHOLDERS:

This report provides an in-depth analysis of the Asia-Pacific IVF market across twelve major countries along with cross sectional analysis of the total number of IVF cycles performed and the total revenue generated during the forecast period.
The report includes the strategies adopted by various IVF clinics and hospitals across major countries to capitalize on the latent opportunities in the Asia-Pacific IVF market.
This report comprehensively analyzes the market scenario across different countries in the Asia-Pacific region.
The projections in this report are made by analyzing the current market trends and highlighting the market potential, in terms of value and volume, from 2015 to 2022.
Extensive analysis of the market is conducted by following the key product positioning and monitoring the top contenders.

KEY MARKET SEGMENTS:

By End Users (Value and Volume)

Fertility Clinics
Hospitals
Surgical Centers
Clinical Research Institutes

By Cycle Type, (Value and Volume)

Fresh Cycle (Non-Donor)
Thawed IVF Cycle (Non-Donor)
Donor Egg IVF Cycles

By Cycle Type Country Level Analysis (Value and Volume)

India
China
Japan
Australia
New Zealand
Korea
Thailand
Singapore
Malaysia
Indonesia
Philippines
Vietnam
Rest of Asia-Pacific
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Auxogyn Inc.
  • Cook Medicals
  • Cooper Surgical. Inc.
  • EMD Serono Inc.
  • Genea Biomedx
  • Irvine Scientific Inc.
  • MORE

CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Coverage and limitations
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 ASIA-PACIFIC IVF MARKET ANALYSIS
3.1 Market definition and scope
3.2 Overview
3.3 Drivers
3.3.1 Delay in family planning reduces chances of conception
3.3.2 Decline in birth rate
3.3.3 Emotional problems
3.4 Restraints
3.5 Asia-Pacific embryo transfer market, by Country
3.6 Asia-Pacific embryo transfer market by Cycle Types
3.7 Asia-Pacific embryo transfer market by End Users
3.8 Company Profile
3.8.1 Thermo Fisher Scientific, Inc.
3.8.2 Merck KGaA

CHAPTER 4 INDIA EMBRYO TRANSFER MARKET
4.1 Overview
4.2 India Embryo Transfer Market by End Users
4.2.1 Fertility clinics
4.2.2 Hospitals
4.2.3 Surgical centers
4.2.4 Clinical research institutes
4.3 India IVF Market by Cycle Type
4.3.1 Fresh IVF cycles (non-donor)
4.3.2 Thawed IVF cycles (non-donor)
4.3.3 Donor egg IVF cycles
4.4 Drivers
4.5 Restraints
4.6 Regulatory issues, legislations, and authorities
4.7 Insurance reimbursement scenario
4.8 Company/Hospitals/Clinics Profile
4.8.1 Sun Pharmaceutical Industries Ltd.
4.8.2 Trivector Origio Scientific Pvt. Ltd
4.8.3 Lab IVF Asia Pte. Ltd.
4.8.4 LG Life Sciences.
4.8.5 Cadila Healthcare Ltd. (Zydus Cadila group)
4.8.6 Bourn Hall Clinic
4.8.7 Morpheus IVF Fertility Center
4.8.8 Southend Fertility and IVF Centre
4.8.9 Nova IVI Fertility
4.8.10 Bloom Fertility Center
4.8.11 Manipal Ankur
4.8.12 Cloudnine

CHAPTER 5 CHINA EMBRYO TRANSFER MARKET
5.1 Overview
5.2 China Embryo Transfer Market by End Users
5.2.1 Fertility clinics
5.2.2 Hospitals
5.2.3 Surgical centers
5.2.4 Clinical research institutes
5.3 China IVF Market by Cycle Type
5.3.1 Fresh IVF cycles (non-donor)
5.3.2 Thawed IVF cycles (non-donor)
5.3.3 Donor egg IVF cycles
5.4 Drivers
5.4.1 Increased rate of infertility
5.4.2 Change in lifestyle
5.5 Restraints
5.5.1 Cost of living
5.6 Regulatory issues, legislations, and authorities
5.7 Insurance reimbursement scenario
5.8 Company/Hospitals/Clinics Profile
5.8.1 Cook Medical, Inc.
5.8.2 Vitrolife AB
5.8.3 Centre for Reproductive Medicine
5.8.4 Reproductive & Genetic Hospital Citic-Xiangya
5.8.5 Shenyang International Hospital
5.8.6 Shandong Provincial Hospital

CHAPTER 6 JAPAN EMBRYO TRANSFER MARKET
6.1 Overview
6.2 Japan Embryo Transfer Market by End Users
6.2.1 Fertility clinics
6.2.2 Hospitals
6.2.3 Surgical centers
6.2.4 Clinical research institutes
6.3 Japan IVF Market by Cycle Type
6.3.1 Fresh IVF cycles (non-donor)
6.3.2 Thawed IVF cycles (non-donor)
6.4 Drivers
6.5 Restraints
6.6 Regulatory issues, legislations, and authorities
6.7 Insurance reimbursement scenario
6.8 Company/Hospitals/Clinics Profile
6.8.1 Merck KGaA
6.8.2 IVF Namba Clinic
6.8.3 Iwaki Womens Clinic
6.8.4 Sanno Hospital

CHAPTER 7 AUSTRALIA EMBRYO TRANSFER MARKET
7.1 Overview
7.2 Australia Embryo Transfer Market by End Users
7.2.1 Fertility clinics
7.2.2 Hospitals
7.2.3 Surgical centers
7.2.4 Clinical research institutes
7.3 Australia IVF Market by Cycle Type
7.3.1 Fresh IVF cycles (non-donor)
7.3.2 Thawed IVF cycles (non-donor)
7.4 Drivers
7.5 Restraints
7.5.1 Emotional and physical stress
7.5.2 No guarantee
7.5.3 Surplus embryos
7.6 Regulatory issues, legislations, and authorities
7.6.1 Common Law
7.6.2 Legislative responses to IVF
7.6.3 Non-legislative regulation for the practice of IVF
7.7 Insurance reimbursement scenario
7.8 Company/Hospitals/Clinics Profile
7.8.1 Genea Biomedx
7.8.2 Thermo Fisher Scientific, Inc.
7.8.3 Virtus Health
7.8.4 Monash IVF
7.8.5 City Fertility
7.8.6 Flinders Fertility

CHAPTER 8 NEW ZEALAND EMBRYO TRANSFER MARKET
8.1 Overview
8.2 New Zealand Embryo Transfer Market by End Users
8.2.1 Fertility clinics
8.2.2 Hospitals
8.2.3 Surgical centers
8.2.4 Clinical research institutes
8.3 New Zealand IVF Market by Cycle Type
8.3.1 Fresh IVF cycles (non-donor)
8.3.2 Thawed IVF cycles (non-donor)
8.3.3 Donor egg IVF cycles
8.4 Drivers
8.5 Restraints
8.6 Regulatory issues, legislations, and authorities
8.7 Insurance reimbursement scenario
8.8 Hospitals/Clinics Profile
8.8.1 Fertility Associates
8.8.2 Fertility Plus
8.8.3 Reporomed

CHAPTER 9 KOREA EMBRYO TRANSFER MARKET
9.1 Overview
9.2 Korea Embryo Transfer Market by End Users
9.2.1 Fertility clinics
9.2.2 Hospitals
9.2.3 Surgical centers
9.2.4 Clinical research institutes
9.3 Korea IVF Market by Cycle Type
9.3.1 Fresh IVF cycles (non-donor)
9.3.2 Thawed IVF cycles (non-donor)
9.3.3 Donor egg IVF cycles
9.4 Drivers
9.5 Restraints
9.6 Regulatory issues, legislations, and authorities
9.7 Insurance reimbursement scenario
9.8 Hospitals/Clinics Profile
9.8.1 Cha General Hospital
9.8.2 Maria Fertility Hospital

CHAPTER 10 THAILAND EMBRYO TRANSFER MARKET
10.1 Overview
10.2 Thailand Embryo Transfer Market by End Users
10.2.1 Fertility clinics
10.2.2 Hospitals
10.2.3 Surgical centers
10.2.4 Clinical research institutes
10.3 Thailand IVF Market by Cycle Type
10.3.1 Fresh IVF cycles (non-donor)
10.3.2 Thawed IVF cycles (non-donor)
10.3.3 Donor egg IVF cycles
10.4 Drivers
10.4.1 Government initiatives
10.4.2 Surrogacy is economical as compared to developed countries
10.4.3 Boost in medical tourism
10.5 Restraints
10.5.1 Comparatively low success rate
10.5.2 Ethical issues in allowing gender selection
10.6 Regulatory issues, legislations, and authorities
10.7 Insurance reimbursement scenario
10.8 Hospitals/Clinics Profile
10.8.1 Bangkok Fertility Center
10.8.2 Siriraj Hospital
10.8.3 Ramathibodi Hospital
10.8.4 Perfect Woman Institute Piyavate Hospital
10.8.5 Jetanin Institute for Assisted Reproduction

CHAPTER 11 SINGAPORE EMBRYO TRANSFER MARKET
11.1 Overview
11.2 Singapore Embryo Transfer Market by End Users
11.2.1 Fertility clinics
11.2.2 Hospitals
11.2.3 Surgical centers
11.2.4 Clinical research institutes
11.3 Singapore IVF Market by Cycle Type
11.3.1 Fresh IVF cycles (non-donor)
11.3.2 Thawed IVF cycles (non-donor)
11.4 Drivers
11.4.1 Government funding and tax rebates for parents
11.4.2 Rising infertility rate
11.4.3 Increase in success rate
11.5 Restraints
11.5.1 High cost of IVF treatment and lower success rate
11.6 Regulatory issues, legislations, and authorities
11.7 Insurance reimbursement scenario
11.8 Company/Clinics Profile
11.8.1 Irvine Scientific
11.8.2 ESCO Technologies Inc.
11.8.3 Leica Microsystems GMBH
11.8.4 NUH IVF Centre
11.8.5 Mount Elizabeth Fertility Center
11.8.6 Thomson Fertility Centre
11.8.7 Raffles Fertility Centre

CHAPTER 12 MALAYSIAN EMBRYO TRANSFER MARKET
12.1 Overview
12.2 Malaysia Embryo Transfer Market by End Users
12.2.1 Fertility clinics
12.2.2 Hospitals
12.2.3 Surgical centers
12.2.4 Clinical research institutes
12.3 Malaysia IVF Market by Cycle Type
12.3.1 Fresh IVF cycles (non-donor)
12.3.2 Thawed IVF cycles (non-donor)
12.3.3 Donor egg IVF cycles
12.4 Drivers
12.4.1 Increase in government initiatives
12.4.2 Increase in the number of foreign patients
12.4.3 Decrease in rate of fertility and growing acceptability of IVF
12.5 Restraints
12.6 Regulatory issues, legislations, and authorities
12.7 Insurance reimbursement scenario
12.8 Clinics Profile
12.8.1 Subang Fertility Center
12.8.2 Concept Fertility Centre
12.8.3 TMC Fertility Center

CHAPTER 13 INDONESIAN EMBRYO TRANSFER MARKET
13.1 Overview
13.2 Indonesia Embryo Transfer Market by End Users
13.2.1 Fertility clinics
13.2.2 Hospitals
13.2.3 Surgical centers
13.2.4 Clinical research institutes
13.3 Indonesia IVF Market by Cycle Type
13.3.1 Fresh IVF cycles (non-donor)
13.3.2 Thawed IVF cycles (non-donor)
13.3.3 Donor egg IVF cycles
13.4 Drivers
13.4.1 Increase in disposable income
13.4.2 Advances in embryo transfer technology
13.4.3 Decline in fertility rate
13.5 Restraints
13.5.1 Physical and emotional impact due to low success rate
13.6 Regulatory issues, legislations, and authorities
13.7 Insurance reimbursement scenario
13.8 Clinics Profile
13.8.1 Morula IVF
13.8.2 Yasmin IVF
13.8.3 Aster Fertility Clinic
13.8.4 Fertility Centre, Siloam Hospitals Surabana

CHAPTER 14 PHILIPPINES EMBRYO TRANSFER MARKET
14.1 Overview
14.2 Philippines Embryo Transfer Market by End Users
14.2.1 Fertility clinics
14.2.2 Hospitals
14.2.3 Surgical centers
14.2.4 Clinical research institutes
14.3 Philippines IVF market by cycle type
14.3.1 Fresh IVF cycles (non-donor)
14.3.2 Thawed IVF cycles (non-donor)
14.3.3 Donor egg IVF cycles
14.4 Drivers
14.4.1 Improve the replacement population
14.4.2 Advancement in technology
14.5 Restraints
14.6 Regulatory issues, legislations, and authorities
14.7 Insurance reimbursement scenario
14.8 Clinic Profile
14.8.1 Victory Art Lab
14.8.2 CRM-MIA-Philippines

CHAPTER 15 VIETNAM EMBRYO TRANSFER MARKET
15.1 Overview
15.2 Vietnam Embryo Transfer Market by End Users
15.2.1 Fertility clinics
15.2.2 Hospitals
15.2.3 Surgical centers
15.2.4 Clinical research institutes
15.3 Vietnam IVF market by cycle type
15.3.1 Fresh IVF cycles (non-donor)
15.3.2 Thawed IVF cycles (non-donor)
15.3.3 Donor egg IVF cycles
15.4 Drivers
15.4.1 Decline in fertility rate
15.4.2 Reasonable cost and good success rate
15.5 Restraints
15.6 Regulatory issues, legislations, and authorities
15.7 Insurance reimbursement scenario
15.8 Hospital/Clinic Profile
15.8.1 IVF Lab Tu Du Hospital Vietnam
15.8.2 IVF Van Hanh
15.8.3 Sinh Hospital
15.8.4 Tu Du - Ho Chi Minh City Vietnam

CHAPTER 16 REST OF ASIA-PACIFIC EMBRYO TRANSFER MARKET
16.1 Overview
16.2 Rest of Asia-Pacific Embryo Transfer Market by End Users
16.2.1 Fertility clinics
16.2.2 Hospitals
16.2.3 Surgical centers
16.2.4 Clinical research institutes
16.3 Rest of Asia-Pacific IVF Market by Cycle Type
16.3.1 Fresh IVF cycles (non-donor)
16.3.2 Thawed IVF cycles (non-donor)
16.3.3 Donor egg IVF cycles
16.4 Drivers
16.4.1 Increase in disposable income
16.4.2 Advances in IVF technology
16.4.3 Decline in fertility rate
16.5 Restraints
16.5.1 Physical and emotional impact due to low success rate
16.6 Regulatory Issues, legislations, and Authorities
16.7 Insurance Reimbursement Scenario
16.8 Hospitals/Clinics Profile
16.8.1 Fertility Centre, Siloam Hospitals Surabana
16.8.2 CRM-MIA-Philippines
16.8.3 IVFAS

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Auxogyn Inc.
  • Cook Medicals
  • Cooper Surgical. Inc.
  • EMD Serono Inc.
  • Genea Biomedx
  • Irvine Scientific Inc.
  • MORE

Asia-Pacific In-vitro Fertilization (IVF) Services Market Report, forecasts that the Asia-Pacific Market is expected to reach $7 billion by 2022, growing at a CAGR of 13.3% from 2016 to 2022. The fresh cycle (non-donor) segment accounted for approximately three-fourths share in 2015 and is expected to maintain its dominance during the forecast period.

Changing lifestyle conditions, reduced conceiving rates in women above 40 years, delay in pregnancy in women suffering from gynecological conditions, and fertility disorders followed by favorable reimbursement scenario and delayed parenthood opted by couples due to professional and financial constraints are some of the major factors that drive the market growth. The Asia-Pacific IVF market is estimated to grow at a CAGR of 13.3% during 2016-2022.

The rapidly growing geriatric population has been a major concern for the government in most of the countries in the Asia-Pacific region. Several countries, such as Vietnam, Cambodia, and Philippines, have fertility rates of 2 births per woman, which is below the average rate of 2.1 births per woman. These countries are keen on boosting their fertility rates to maintain balance between new born and geriatric populations. Indonesia in particular had a fertility rate of 2.1 and geriatric population of about 5% of the total population in 2015. According to AgeingAsia.org, this number is anticipated to reach 74 million by 2050. Korea, which had a fertility rate of 1.25 in 2014, has announced financial support for infertility treatment. Similarly, Singapore, with fertility rate of 0.80 in 2014, has increased the subsidy for treatment to 75% of the treatment cost. These factors have been instrumental in driving the growth of the Asia-Pacific embryo transfer market.

In the end user segment, fertility clinics accounted for major share of the Asia-Pacific IVF market in 2015, and is projected to maintain this trend throughout the forecast period. The rise can be attributed to rise in the number of fertility clinics as well as the availability of wide range of fertility treatments under one roof coupled with government reimbursements. Fertility clinics are followed by hospitals in terms of revenue generation and together with fertility clinics they occupy approximately four-fifth share of the overall Asia-Pacific market.

Key Findings of the Asia-Pacific In-vitro Fertilization (IVF) Services Market:

  • Hospitals is projected to be the fastest growing segment.
  • India is forecast to be the fastest growing country in Asia-Pacific IVF market, growing at a CAGR of 16.6% from 2016 to 2022 in terms of revenue.
  • In 2015, China and Japan collectively accounted for approximately two-thirds share of the Asia-Pacific IVF market volume.
  • Fresh cycle (non-donor) would be the highest revenue generating segment followed by Thawed IVF cycle (non-donor) during 2016-2022.
  • Thawed IVF cycle (non-donor) will be the fastest growing segment in Vietnam during 2016-2022 growing at a CAGR of 8.2% in terms of volume.
  • Japan is the highest revenue-generating region in 2015, owing to the widespread adoption of IVF techniques. However, India is expected to grow rapidly during the forecast period, owing to the growth in cost per cycle due to increasing sophistications of procedures and advancements in technology.
Note: Product cover images may vary from those shown
5 of 6
  • Vitrolife AB
  • Cooper Surgical. Inc.
  • Cook Medicals
  • Thermo Fisher Scientific
  • Irvine Scientific Inc.
  • Genea Biomedx
  • Oxford Gene Technology
  • Auxogyn Inc.
  • EMD Serono Inc.
  • Ovascience Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll